<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336516">
  <stage>Registered</stage>
  <submitdate>16/02/2011</submitdate>
  <approvaldate>21/02/2011</approvaldate>
  <actrnumber>ACTRN12611000197932</actrnumber>
  <trial_identification>
    <studytitle>Effects of acute ketamine administration on mental representations of the body in healthy participants.</studytitle>
    <scientifictitle>Effects of acute ketamine administration on mental representations of the body in healthy participants.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.16 mg/kg I.V. dose of ketamine administered over an hour.</interventions>
    <comparator>Placebo (saline solution) administered once. This is a cross-over trial with a minimum washout between drug and placebo of 14 days, maximum washout of 28 days and a mode (most frequent) of 14 days.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proprioceptive Drift in the Projected Hand Illusion</outcome>
      <timepoint>20 mins after initial dosing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subjective Experience of the Projected Hand Illusion Questionnaire</outcome>
      <timepoint>30 mins after initial dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma ketamine level</outcome>
      <timepoint>0 and 90 mins after initial dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy participants</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Pregnancy or currently breastfeeding
2. Neurological disorders or known seizure risk
3. History of loss of consciousness for over 5 mins
4. Current diagnosis or treatment for a mental illness
5. Past or current treatment for substance use disorder
6. Significant risk of psychoses (previous history of psychosis or first-degree relative diagnosed with schizophrenia/schizophrenia-spectrum disorders)
7. Presence or history of a kinetic disorder
8. Presence or history of hypertension
9. Presence or history of hepatic insufficiency
10. Presence of renal insufficiency
11. Presence or history of cardiovascular disorder
12. Significant risk of suicide
13. Known hypersensitivity to ketamine
14. Receiving any systematic prescription medication (excluding oral contraceptive pill)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>This is a within-subject treatment design where the order of treatment (placebo or drug first) is randomised. The person who determines the eligibility for inclusion in the trial is unaware of the treatment being allocated on the day of assessment and medical examination. Allocation of the order of treatment is randomised by the chief investigator (Mathew Martin-Iverson) off-site with a random number table, who does not assess the participants' suitability, does not test the participants or analyse the data. Participants are provided information on the study by an experimenter who is blind to the allocation. Interview and medical examination and decision to include/exclude from the study is conducted by one of two psychiatrists who are unaware of the allocation of treatment schedule.</concealment>
    <sequence>Simple randomisation of treatment order by random number table.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Placebo</designfeatures>
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>4/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof. Mathew Martin-Iverson</primarysponsorname>
    <primarysponsoraddress>University of Western Australia
35 Stirling Highway
Crawley, WA
6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Australia</fundingname>
      <fundingaddress>35 Stirling Highway
Crawley, WA
6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof Flavie Waters</sponsorname>
      <sponsoraddress>University of Western Australia
35 Stirling Highway
Crawley, WA
6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof. Thomas Ledowski</othercollaboratorname>
      <othercollaboratoraddress>University of Western Australia
35 Stirling Highway
Crawley, WA
6009</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Kyran Graham</othercollaboratorname>
      <othercollaboratoraddress>CCRN
Gascoyne House
John XXIII Avenue
Mt Claremont Western Australia 6010</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine whether or not acute ketamine administration produces schizophrenic-like changes in the way one's own body is represented mentally.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>North Metropolitan Area Mental Health Services 
Human Research Ethics Committee</ethicname>
      <ethicaddress>Graylands Hospital,
Mt Claremont, WA
6010</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>16/03/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. Mathew Martin-Iverson</name>
      <address>University of Western Australia
35 Stirling Highway
Crawley, WA
6009</address>
      <phone>+61 8 9347 6443</phone>
      <fax>+61 8 9384-4128</fax>
      <email>mathew@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. Mathew Martin-Iverson</name>
      <address>University of Western Australia
35 Stirling Highway
Crawley, WA
6009</address>
      <phone>+61 8  9347 6430</phone>
      <fax>+61 8 9384-4128</fax>
      <email>mathew@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. Mathew Martin-Iverson</name>
      <address>University of Western Australia
35 Stirling Highway
Crawley, WA
6009</address>
      <phone>+61 8 9347 6443</phone>
      <fax>+61 8 9384-4128</fax>
      <email>mathew@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>